Loading…
Reported covered position: ASSOCIATE
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
VALID Act of 2023
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation; VALID Act (H.R. 2369)
VALID Act of 2023
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation; VALID Act (H.R. 2369)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2026 · second_quarter · Q2
Potential legislation for regulation of laboratory diagnostics.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2026 · first_quarter · Q1
Source: Senate LDA
VALID Act of 2023
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation; VALID Act (H.R. 2369)
Consolidated Appropriations Act, 2023
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
Food and Drug Amendments of 2022
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
PREVENT Pandemics Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
PREVENT Pandemics Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
PREVENT Pandemics Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response.
PREVENT Pandemics Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
FDASLA Act of 2022
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
FDASLA Act of 2022
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
Saving Access to Laboratory Services Act
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); Coronavirus impact and response.
VALID Act of 2021
Client: AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) · Firm: COVINGTON & BURLING LLP
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); Coronavirus impact and response.
Potential legislation for regulation of laboratory diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2025 · fourth_quarter · Q4
Potential legislation for regulation of laboratory diagnostics.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2025 · third_quarter · Q3
Potential legislation for regulation of laboratory diagnostics; discussion of Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2025 · second_quarter · Q2
Potential legislation for regulation of laboratory diagnostics; discussion of Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2025 · first_quarter · Q1
Potential legislation for regulation of laboratory diagnostics; discussion of Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2024 · fourth_quarter · Q4
Discussion of Food and Drug Administration (FDA) policies and authority related to diagnostics and laboratory regulation.
Filing targets: HOUSE OF REPRESENTATIVES
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2024 · third_quarter · Q3
Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation; VALID Act (H.R. 2369)
Filing targets: SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2024 · second_quarter · Q2
Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation; VALID Act (H.R. 2369)
Filing targets: HOUSE OF REPRESENTATIVES
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2024 · first_quarter · Q1
Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation; VALID Act (H.R. 2369)
Filing targets: HOUSE OF REPRESENTATIVES
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2023 · third_quarter · Q3
Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation.
Filing targets: Executive Office of the President (EOP), Office of Management & Budget (OMB)
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2023 · second_quarter · Q2
Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation.
Filing targets: Food & Drug Administration (FDA)
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2023 · first_quarter · 1A
Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) policies related to diagnostics and laboratory regulation; reauthorization of the Pandemics and All-Hazards Preparedness Act (PAHPA).
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Consolidated Appropriations Act, 2023 (H.R.2617); Saving Access for Laboratory Services Act (S. 4449/H.R. 8188).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348); Food and Drug Amendments of 2022 (H.R.7667).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response; FDASLA Act of 2022 (S. 4348).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); PREVENT Pandemics Act (S. 3799); Coronavirus impact and response.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (S. 2209/H.R. 4128); Coronavirus impact and response.
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Policies impacting Medicare coverage and reimbursement for clinical laboratory services; FDA regulation of clinical laboratory services; Coronavirus impact and response.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2020 · fourth_quarter · Q4
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
Appropriations funding in response to COVID pandemic; Medicare funding (*Brendan Parets did not lobby the U.S. Senate*)
Appropriations funding in response to COVID pandemic; Medicare funding (*Brendan Parets did not lobby the U.S. Senate*)
Appropriations funding in response to COVID pandemic; Medicare funding (*Brendan Parets did not lobby the U.S. Senate*)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) via COVINGTON & BURLING LLP
2020 · first_quarter · RA
Appropriations funding in response to COVID pandemic; Medicare funding
Appropriations funding in response to COVID pandemic; Medicare funding
PARAMOUNT BIOCAPITAL ASSET MANAGEMENT via COVINGTON & BURLING LLP
2006 · mid_year · MM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARAMOUNT BIOCAPITAL ASSET MANAGEMENT via COVINGTON & BURLING LLP
2006 · mid_year · RR